The packet supplies no diagnostic criteria or testing information. Trial titles refer to cervical screening algorithms and primary HPV testing for cervical screening, but these titles do not establish diagnostic standards.

The packet supplies no approved treatments, foundational therapies, or expert management guidance for cervical intraepithelial neoplasia, so treatment information is not certified in this packet. Interventions named in trial titles are under study and are not established treatments on that basis alone.

Prognosis is not certified in this packet; no natural history or outcome information is supplied.

ClinicalTrials.gov records in the packet include numerous active studies matched to cervical intraepithelial neoplasia. Listed records include a phase 2 study titled Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia (NCT04712851, active, not recruiting, sponsored by Jonsson Comprehensive Cancer Center), a phase 1 study of an HPV DNA vaccine via electroporation for HPV16 positive cervical neoplasia (NCT04131413, recruiting, Johns Hopkins), and a phase 1 study of fenofibrate in patients with cervical intraepithelial neoplasia and invasive cervical carcinoma (NCT06191133, recruiting). Other records examine vaginal gel and suppository products, screening strategies in people with HIV, and a smoking abstinence study in cervical cancer survivors. Trial titles alone do not establish efficacy or approval of any intervention.